ライフサイエンスコーパス: cardioversion

1 fidence interval 0.01 to 1.0, for electrical cardioversion).

2 ditional antiarrhythmic agents for sustained cardioversion.

3 y (n = 25), presented for ibutilide (2.0 mg) cardioversion.

4 ce could provide a more effective option for cardioversion.

5 recurrence of atrial fibrillation (AF) after cardioversion.

6 ients with AF/atrial flutter referred for DC cardioversion.

7 ategy of maintenance of sinus rhythm without cardioversion.

8 gies for those patients who elect to undergo cardioversion.

9 be rare or repeatedly induce AF and require cardioversion.

10 atients had IART recurrence and 28% required cardioversion.

11 n for anticoagulation for three weeks before cardioversion.

12 ion does not increase the rate of successful cardioversion.

13 he management of patients with AF undergoing cardioversion.

14 ding complications and safely expedite early cardioversion.

15 enefit of Mg in facilitating pharmacological cardioversion.

16 tant to most chemical methods and electrical cardioversion.

17 emaking, arrhythmogenesis and suppression or cardioversion.

18 titachycardia pacing, and AF, which requires cardioversion.

19 endent on the duration of sinus rhythm after cardioversion.

20 lar accident occurred within one month after cardioversion.

21 induce atrial contractile dysfunction after cardioversion.

22 hold protective anticoagulation for internal cardioversion.

23 ctory to standard energy direct current (DC) cardioversion.

24 , 300, and 360 J were used for transthoracic cardioversion.

25 ibrillation refractory to standard energy DC cardioversion.

26 t is resistant to conventional transthoracic cardioversion.

27 to sinus rhythm by transthoracic electrical cardioversion.

28 t thrombus resolution) is recommended before cardioversion.

29 ricular tachycardia requiring direct current cardioversion.

30 /ml (normal < 6.7) in only one patient after cardioversion.

31 ful in 38 of 45 patients (84%) who had early cardioversion.

32 re drawn before and 8, 16, 24 and 48 h after cardioversion.

33 d extrastimulation a considerable time after cardioversion.

34 stability occurring as long as 4 weeks after cardioversion.

35 ty ratio (2.5 +/- 1.2 vs. 1.5 +/- 0.5) after cardioversion.

36 fibrillation who were scheduled for electric cardioversion.

37 nts suffered transient ischemic attack after cardioversion.

38 30 days (median 2 days, mean 4.6 days) after cardioversion.

39 stent atrial fibrillation undergoing planned cardioversion.

40 F recurrence in patients undergoing electric cardioversion.

41 with AF recurrence in patients who underwent cardioversion.

42 prevent recurrent atrial fibrillation after cardioversion.

43 lternative to warfarin in patients requiring cardioversion.

44 de of torsade de pointes requiring immediate cardioversion.

45 nto 2 categories: antitachycardia pacing and cardioversion.

46 ing with only 13% of the energy required for cardioversion.

47 lar tachycardia during mapping that required cardioversion.

48 n) also increased from initial to subsequent cardioversions.

49 or noninferiority), and was mainly driven by cardioversions.

50 ive amount of energy required for successful cardioversion (123.3+/-55.5 versus 129.5+/-52.6 J; P=0.4

51 Of the 46 successful cardioversions, 18 patients (39%) remained in sinus rhyt

52 During 144 electrical cardioversions, 209 shocks were delivered to 72 patients

53 The responses to cardioversion, ablation, and rapid pacing observed in th

54 <1 year), or permanent (>/=1 year or failed cardioversion) AF patterns at randomization.

55 lso no improvement in the rate of successful cardioversion after first shock (AOR, 0.73; 95% CI, 0.51

56 difference in unadjusted rate of successful cardioversion after first shock (from 12.3% to 13.8%; P=

57 In all 14 patients in whom transthoracic cardioversion alone failed, sinus rhythm was restored wh

58 In the lowest-risk cohort (1.6% per year), cardioversion alone followed by aspirin therapy on relap

59 gh risk for ischemic stroke (5.3% per year), cardioversion alone followed by repeated cardioversion p

60 ost-effective ($9300 per QALY) compared with cardioversion alone followed by warfarin therapy on rela

61 Cardioversion alone should be the initial management str

62 Strategies involving cardioversion alone were more effective and less costly

63 c strategies using different combinations of cardioversion alone, cardioversion plus amiodarone or qu

64 d directly measured refractory periods after cardioversion) also increased from initial to subsequent

65 agulation, rhythm management with electrical cardioversion, amiodarone, or both is preferred.

66 ofetilide: 1) before elective direct current cardioversion and 2) within 24 h of restoration of SR.

67 in 20 of 23 (87%) attempts at direct current cardioversion and 7 of 22 (32%) attempts at transesopheg

68 he TEE-guided strategy had a shorter time to cardioversion and a lower rate of composite bleeding.

69 occurrence and frequency of documented IART, cardioversion and arrhythmia-related hospital visits bef

70 code was called, and he was stabilized after cardioversion and bedside intubation.

71 seful in estimating likelihood of successful cardioversion and maintenance.

72 thin the same setting of the failed standard cardioversion and obviates the need to withhold protecti

73 Slower heart rates after cardioversion and QT dispersion during treatment appear

74 ctomy presented to our hospital for elective cardioversion and rate control with tikosyn.

75 were frequency of cardioversion and times to cardioversion and sinus rhythm.

76 e to first shock and lead to higher rates of cardioversion and survival compared with a manual strate

77 th chronic AF in humans are reversible after cardioversion and that the extent of this reversal is de

78 hythm, as well as the efficacy of electrical cardioversion and the use of echocardiography in patient

79 sibility outcome variables were frequency of cardioversion and times to cardioversion and sinus rhyth

80 the treatment of atrial fibrillation: one is cardioversion and treatment with antiarrhythmic drugs to

81 cost of TTE, cost of hospital admission for cardioversion and utilities for health states.

82 There was a trend toward fewer cardioversions and hospital admissions after AIT.

83 with a risk of cerebral emboli attributed to cardioversions and numerous ablation lesions in the low-

84 s alive, in sinus rhythm, with no additional cardioversions and still taking the assigned drug at one

85 Acute restoration (ie, cardioversion) and maintenance of sinus rhythm in patien

86 after ibutilide were treated with electrical cardioversion, and 35 (90%) of 39 patients were successf

87 mary treatment in 63% of cases, 1% underwent cardioversion, and 92% were in sinus rhythm on discharge

88 rol in most patients, decreases the need for cardioversion, and antithrombotic therapy can be selecti

89 crease the risk for embolism associated with cardioversion, and may be associated with less clinical

90 ation on the time to first shock, successful cardioversion, and patient outcomes was assessed using i

91 formation, maintenance of sinus rhythm after cardioversion, and techniques of left atrial appendage o

92 rrelate to longer duration of AF, success of cardioversion, and thrombogenesis.

93 ary sinus ostium) and the long-term need for cardioversion, antithrombotic and antiarrhythmic drug th

94 Direct current cardioversion appears to be most effective at establishi

95 icoagulation, a TEE-guided approach to early cardioversion appears to have a safety profile similar t

96 andomisation (block size four)-stratified by cardioversion approach (transoesophageal echocardiograph

97 t edoxaban in patients undergoing electrical cardioversion are available.

98 Patients undergoing cardioversion are treated conventionally with therapeuti

99 ng intervals of atrial premature beats after cardioversion as measures of atrial refractoriness.

100 Of 40 patients with successful cardioversion, atrial mechanical activity was absent in

101 ibutilide was administered and transthoracic cardioversion attempted again.

102 Cardioversion attempts with the device were assessed in

103 It may be a useful alternative to internal cardioversion because it could be done within the same s

104 ectively randomized to either direct current cardioversion before PVAI and posterior wall/septum abla

105 ignificant difference in the success rate of cardioversion between the 2 groups (86.4% versus 86.0%;

106 cent of patients had an increase in CK after cardioversion, but CK-MB was elevated to an abnormal lev

107 rdiopulmonary resuscitation, defibrillation, cardioversion, cardiac pacing, or treatments targeted at

108 and around the time of procedures including cardioversion, catheter ablation, and device implantatio

109 tilide is greater in sinus rhythm (SR) after cardioversion compared with during atrial fibrillation (

110 ents in whom early cardioversion is desired: Cardioversion could be delayed in patients with a high l

111 ibrillation (AF) after successful electrical cardioversion (CV).

112 ts with AF >2 days undergoing direct current cardioversion (DCC).

113 MIRACLE ICD (Multicenter InSync Implantable Cardioversion Defibrillation Randomized Clinical Evaluat

114 The most frequent triggering events were cardioversion/defibrillation (72, 0.6%), unplanned use o

115 he need for ICD therapies, including ATP and cardioversion/defibrillation (ICD shocks) in patients wi

116 Direct current cardioversion/defibrillation is an important part of the

117 ardia to optimize mechanistic, multi-barrier cardioversion/defibrillation patterns.

118 % versus 27 +/- 18%; P = 0.01), and external cardioversion/defibrillation shocks (20% versus 65.2%; P

119 Patients who undergo electrical cardioversion display a greater degree and a longer dura

120 signed to receive amiodarone and undergo two cardioversions during the first three months alone (the

121 We compared the incidence of electrical cardioversion (ECV), pharmacologic cardioversion (PCV),

122 hocks to periods of high organization of AF, cardioversion efficacy should improve.

123 nduction block were created with a very high cardioversion efficiency but with lower energy requireme

124 This study is the largest cardioversion experience to date and the first to evalua

125 in acute PVI nonresponder, if direct current cardioversion failed after PVI.

126 ent of the placebo group, and direct-current cardioversion failed in 27.7 percent, 26.5 percent, and

127 Standard external electrical cardioversion fails to restore sinus rhythm in 5% to 30%

128 The efficacy of transthoracic cardioversion for converting atrial fibrillation to sinu

129 nt trial, the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation study,

130 In patients undergoing electric cardioversion for persistent atrial fibrillation, Mg inf

131 assess the efficacy and safety of ibutilide cardioversion for those with atrial fibrillation (AF) or

132 ioversion from atrial flutter and those with cardioversion from AF.

133 elocities measured during sinus rhythm after cardioversion from atrial fibrillation are depressed rel

134 ignificant differences between patients with cardioversion from atrial flutter and those with cardiov

135 In patients with cardioversion from atrial flutter or AF, the steady stat

136 des of atrial fibrillation (AF) that require cardioversion from self-terminating episodes that do not

137 in atrial fibrillation, both direct-current cardioversion (Grade: 1C+) and pharmacological conversio

138 domization protocol to receive either direct cardioversion (group A) or further ablation of subsequen

139 domized to no further ablation and underwent cardioversion (Group B, n = 50) or to ablation of CFAEs

140 rome, and a new pharmacologic alternative to cardioversion has been introduced.

141 gorithms, antitachycardia pacing, low-energy cardioversion, high-energy shocks, and extensive diagnos

142 significant atrial arrhythmias and need for cardioversion/hospitalization for arrhythmia management.

143 rge and admitted rapidly for repeat internal cardioversion if there was spontaneous AF recurrence.

144 Electrical cardioversion immediately restored sinus rhythm in 102 s

145 sulted in termination of AF without external cardioversion in 115 of the 121 patients (95%); 32 (28%)

146 iate recurrence of AF (IRAF), occurred after cardioversion in 18 of 40 patients, and IRAF was consist

147 avenous amiodarone was used in 46%, electric cardioversion in 28%, and heparin in 26%.

148 al coronary sinus before attempting internal cardioversion in 39 patients with persistent AF.

149 h isoproterenol (up to 20 microg/min) and/or cardioversion in 45 patients with AF were identified usi

150 Biphasic electrical cardioversion in cardiosurgical ICU patients was immedia

151 y and efficacy of higher energy synchronized cardioversion in patients with atrial fibrillation refra

152 ssed the value of this agent in facilitating cardioversion in patients with atrial fibrillation that

153 m, but the efficacy of repetitive electrical cardioversion in restoring sinus rhythm was disappointin

154 support the current recommendation for early cardioversion in these patients.

155 ns in 13 patients for atrial arrhythmia, and cardioversions in 15 patients.

156 ed during the 30 days after 5,116 successful cardioversions in 2,481 patients with neither oral antic

157 AFCL were repeated immediately before repeat cardioversions in the 17 patients who had recurrence of

158 rior anticoagulation followed by early acute cardioversion (in the absence of intracardiac thrombus)

159 view acute methods of heart rate control and cardioversion, including pharmacologic and other minimal

160 External cardioversion is a technique used electively or emergent

161 F, PVAI in sinus rhythm after direct current cardioversion is associated with higher success and shor

162 ecurrence of AF early after ambulatory shock cardioversion is common.

163 ment of therapeutic anticoagulation, whereas cardioversion is delayed in higher risk patients with th

164 ant for management of patients in whom early cardioversion is desired: Cardioversion could be delayed

165 External higher energy cardioversion is effective in restoring sinus rhythm in

166 Immediate electrical cardioversion is indicated when the arrhythmia leads to

167 ort-term antiarrhythmic drug treatment after cardioversion is less effective than is long-term treatm

168 rability to AF initiation 7 to 14 days after cardioversion is more dependent on persisting structural

169 ort-term antiarrhythmic drug treatment after cardioversion is non-inferior to long-term treatment.

170 nfusion of Mg alone in facilitating electric cardioversion is not clear.

171 Next, we make the case that cardioversion is not needed for this asymptomatic patien

172 ponse to antiarrhythmic agents is mixed, and cardioversion is of no avail.

173 tional therapy for patients in whom elective cardioversion is planned.

174 atment for supraventricular tachycardia, but cardioversion is rare in practice (5-20%), necessitating

175 Early access to electrical cardioversion is the key to survival.

176 with new onset AF, conversion by electrical cardioversion is the preferred approach; however, in sta

177 If no thrombus is seen, cardioversion is then performed.

178 l fibrillation who are to undergo electrical cardioversion is to prescribe warfarin for anticoagulati

179 After cardioversion, left atrial appendage flow velocities dec

180 ither spontaneous conversion or treated with cardioversion </=7 days) or persistent (lasting >7 days)

181 uncommon in patients with atrial flutter and cardioversion may be associated with increased risk of t

182 echocardiography reveals no atrial thrombus, cardioversion may be performed safely after only a short

183 ardiography group also had a shorter time to cardioversion (mean [+/-SD], 3.0+/-5.6 vs. 30.6+/-10.6 d

184 est that combination therapy may be a useful cardioversion method for chronic atrial fibrillation or

185 rmed symptomatic paroxysmal AF that required cardioversion (n = 428), at least 2 episodes of AF in th

186 (Safety of Cardioversion of Acute Atrial Fibrillation [FinCV]; NCT0

187 ation therapy is currently recommended after cardioversion of acute atrial fibrillation in patients w

188 tients when no anticoagulation is used after cardioversion of acute atrial fibrillation.

189 actors of thromboembolic complications after cardioversion of acute atrial fibrillation.

190 Previous attempts to perform cardioversion of AF by using an implantable device were

191 For the cardioversion of AF, a biphasic shock waveform has great

192 runcated exponential biphasic shocks for the cardioversion of AF.

193 on or atrial flutter, in patients undergoing cardioversion of atrial arrhythmias and in patients with

194 ide is a class III drug that is used for the cardioversion of atrial arrhythmias, but it can cause to

195 al amiodarone and were referred for elective cardioversion of atrial fibrillation (57 of 70, 81%) or

196 Conventional methods for cardioversion of atrial fibrillation (AF) to sinus rhyth

197 with a conventional monophasic waveform for cardioversion of atrial fibrillation (AF).

198 The effects of cardioversion of atrial fibrillation on the activation s

199 ter trial, patients undergoing transthoracic cardioversion of atrial fibrillation were randomized to

200 For transthoracic cardioversion of atrial fibrillation, rectilinear biphas

201 ve monophasic waveform for the transthoracic cardioversion of atrial fibrillation.

202 oembolic events are thought to be rare after cardioversion of atrial flutter.

203 rs of thromboembolism in patients undergoing cardioversion of atrial flutter.

204 rred to the electrophysiology laboratory for cardioversion of chronic atrial flutter from 1986 to 199

205 n-warfarin in patients undergoing electrical cardioversion of non-valvular atrial fibrillation.

206 ears) underwent successful biphasic electric cardioversion of nonvalvular persistent AF.

207 provoked by isoproterenol (4 microg/min) and cardioversion of pacing-induced AF.

208 e cost-effectiveness of three strategies for cardioversion of patients admitted to the hospital with

209 Electrical cardioversion of patients with atrial fibrillation (AF)

210 omised clinical trial of anticoagulation for cardioversion of patients with non-valvular atrial fibri

211 g regimen of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation (AFib)

212 performed before 25.5%, 24.1%, and 13.3% of cardioversions, of which 1.8%, 1.2%, and 1.1% were posit

213 Cardioversion on randomized treatment was permitted.

214 stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and

215 d death increased in the first 30 days after cardioversion or ablation.

216 Hospitalization increased after cardioversion or AF ablation (HR: 2.01; 95% CI: 1.51 to

217 to 3.42) were not different before and after cardioversion or AF ablation.

218 long-term stroke rates or survival following cardioversion or AF ablation.

219 d ventricular tachycardia requiring external cardioversion or appropriate implantable cardioverter de

220 There are limited data on outcomes following cardioversion or catheter ablation in AF patients treate

221 sought to investigate the outcomes following cardioversion or catheter ablation in patients with atri

222 ot translate into higher rates of successful cardioversion or survival after out-of-hospital cardiac

223 mal (self-limiting), persistent (amenable to cardioversion), or permanent.

224 the effects of antiarrhythmic-drug therapy, cardioversion, or both.

225 ontrol antiarrhythmic drug therapy, electric cardioversion, or catheter ablation in comparison with m

226 evere symptoms requiring hospital admission, cardioversion, or initiation/change of antiarrhythmic dr

227 (AF) >2 days duration undergoing electrical cardioversion over an eight-week period.

228 on (28 +/- 15 before to 15 +/- 14 cm/s after cardioversion, p < 0.001) and atrial flutter (42 +/- 19

229 After successful cardioversion, patients were randomly assigned in permut

230 lectrical cardioversion (ECV), pharmacologic cardioversion (PCV), or AF ablation and subsequent outco

231 Follow-up was 28 days on study drug after cardioversion plus 30 days to assess safety.

232 fferent combinations of cardioversion alone, cardioversion plus amiodarone or quinidine therapy, and

233 r), cardioversion alone followed by repeated cardioversion plus amiodarone therapy on relapse was mos

234 On relapse of arrhythmia, repeated cardioversion plus low-dose amiodarone is cost-effective

235 hour, resulting in symptoms, or treated with cardioversion; postoperative AF excluding atrial flutter

236 story of atrial fibrillation before electric cardioversion/pulmonary vein isolation or after cardioem

237 (AFFIRM) and Rate Control Versus Electrical Cardioversion (RACE) trials that anticoagulation should

238 Pharmacological cardioversion rates for 125, 250, and 500 microgram dofe

239 ctiveness models demonstrate that TEE-guided cardioversion represents a cost-effective strategy, but

240 The device was programmed to deliver cardioversion shocks automatically and/or on patient com

241 currence of atrial fibrillation (ERAF) after cardioversion shocks delivered by permanently implanted

242 epetitive, futile attempts at direct current cardioversion should be avoided.

243 Elective cardioversion should be used cautiously, with attention

244 ransesophageal echocardiography (TEE) before cardioversion should, in many patients, safely permit ca

245 $2,774, QALY 8.49) dominates TTE/TEE-guided cardioversion (strategy 2: cost $3,106, QALY 8.48) and c

246 tivity analyses demonstrated that TEE-guided cardioversion (strategy 3) dominates conventional therap

247 ansesophageal echocardiographic-guided early cardioversion (strategy 3: cost $2,774, QALY 8.49) domin

248 us at very low voltage and energy, with 100% cardioversion success observed for 10-ms 100-V shocks (m

249 The PIAD waveform had a higher cardioversion success rate than a truncated, 70% tilt mo

250 were randomly assigned to receive TEE-guided cardioversion; TEE was done in 56 (90%) of these patient

251 ted OSA have a higher recurrence of AF after cardioversion than patients without a polysomnographic d

252 th AF >2 days duration undergoing electrical cardioversion, the TEE-guided group showed little differ

253 The incidence of post-cardioversion thromboembolic complications is high in ce

254 or those patients who elect to undergo acute cardioversion to achieve sinus rhythm in atrial fibrilla

255 rfarin should be continued for 1 month after cardioversion to allow for more complete recovery of atr

256 sion should, in many patients, safely permit cardioversion to be done earlier than would be possible

257 The use of TEE may allow cardioversion to be done earlier, may decrease the risk

258 for three weeks before and four weeks after cardioversion to decrease the risk of thromboembolism.

259 n at 4 hours and again at 7 to 14 days after cardioversion to sinus rhythm included atrial effective

260 d during a rhythm of atrial flutter or after cardioversion to sinus rhythm.

261 ere was an increase in AFCL from the initial cardioversion to that measured at the time of first AF r

262 inflow Doppler variables were recorded after cardioversion until EMAF (atrial filling velocity > 0.50

263 ere independently associated with successful cardioversion: use of a biphasic waveform (relative risk

264 In contrast, cardioversion uses a single high-voltage shock to termin

265 e randomized to receive Mg or placebo before cardioversion using a step-up protocol with 75, 100, 150

266 Electrical cardioversion using synchronized biphasic shocks.

267 A novel method for cardioversion using the passive implantable atrial defib

268 The Assessment of Cardioversion Using Transesophageal Echocardiography (AC

269 The Assessment of Cardioversion Using Transesophageal Echocardiography (AC

270 ight of the recently completed Assessment of Cardioversion Using Transesophageal Echocardiography (AC

271 (PVAI) in sinus rhythm after direct current cardioversion versus PVAI and ablation targeting complex

272 alone failed, sinus rhythm was restored when cardioversion was attempted again after the administrati

273 Electrical cardioversion was attempted in 4 patients without succes

274 Cardioversion was attempted via 2 atrial defibrillation

275 mpaired left atrial appendage function after cardioversion was less pronounced in the group with atri

276 atment with study drug for >/=3 weeks before cardioversion was lower in D110 (76.4%) and D150 (79.2%)

277 The need for cardioversion was reduced after pacemaker implant (p < 0

278 The time to cardioversion was shorter in the TEE group (0.6 weeks [9

279 The mode of cardioversion was significantly associated with recovery

280 Cardioversion was successful in 38 of 45 patients (84%)

281 If transthoracic cardioversion was unsuccessful in a patient who had not

282 Data from before, during, and 30 days after cardioversion were analyzed.

283 thmia-related hospitalization, or electrical cardioversion were compared.

284 ts with AF (3 to 48 h duration) eligible for cardioversion were enrolled in the study.

285 A total of 1983 cardioversions were performed in 1270 patients: 647, 672

286 A total of 7,660 cardioversions were performed in 3,143 consecutive patie

287 ase, antiarrhythmic drug therapy and mode of cardioversion) were tested for an association with the o

288 3%) converted to sinus rhythm after repeated cardioversions, whereas the remaining 36 (66%) did so sp

289 receiving conventional therapy, 37 (58%) had cardioversion, which was successful in 28 patients (76%)

290 e the former proscribe the use of electrical cardioversion while the latter provide this precise trea

291 r at least two attempts at standard external cardioversion with 360 J were included in the study.

292 Fifty-five patients underwent cardioversion with 720 J.

293 udy was to assess the efficacy and safety of cardioversion with combination therapy in patients with

294 ent is aimed at heart rate control, elective cardioversion with drugs or electrical means, and antico

295 e randomly assigned to undergo transthoracic cardioversion with or without pretreatment with 1 mg of

296 cardioversion anticoagulation versus delayed cardioversion with pre- and postanticoagulation are appr

297 These results suggest that TEE-guided cardioversion with short-term anticoagulation therapy is

298 Seventy percent of pharmacological cardioversions with dofetilide were achieved in 24 hours

299 were in arrhythmia for 196+/-508 days before cardioversion, with a left ventricular ejection fraction

300 a decision-analytic model, TEE-guided early cardioversion, without TTE, is a reasonable cost-saving

301 it is advocated in patients in whom earlier cardioversion would be clinically beneficial.